Paul Schaffer

Prof. Paul Schaffer

TRIUMF
+2
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MNMatthew B. Nodwell
Matthew B. Nodwell
HYHua Yang
Hua Yang
MČMilena Čolović
Milena Čolović
ZYZheliang Yuan
Zheliang Yuan
HMHelen Merkens
Helen Merkens
RBRobert Britton
Robert Britton

1 February 2021 in EJNMMI Radiopharmacy and Chemistry
Verified
Journal Article
Open access
PDF file
BMBrooke L. McNeil
Brooke L. McNeil
ARAndrew K. H. Robertson
Andrew K. H. Robertson
WFWinnie Fu
Winnie Fu
HYHua Yang
Hua Yang
CHCornelia Hoehr
Cornelia Hoehr
PSPaul Schaffer
Paul Schaffer
Background: Lead-212 (212Pb, t1/2 = 10.6 h) and lead-203 (203Pb, t1/2 = 51.9 h) are an element-equivalent, or a matched theranostic radioisotope pair that show great potential for application in targeted radionuclide therapy (TRT) and single-photon emission computed tomography (SPECT), respectively. At TRIUMF we have produced both203Pb and212Pb using TRIUMF’s TR13 (13 MeV) and 500 MeV cyclotrons, and subsequently purified and evaluated both radioisotopes using a series of pyridine-modified DOTA analogues in comparison to the commercially available chelates DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and TCMC (1,4,7,10-tetraaza-1,4,7,10-tetra(2-carbamoylmethyl)cyclododecane).Results: Proton irradiation (12.8 MeV) of natural and enriched thallium-203 (203Tl) targets gave203Pb saturation yields of 134 ± 25 and 483 ± 3 MBq/μA, respectively. Thorium-228 (228Th, t1/2 = 1.9 y), a by-product of232Th proton spallation on TRIUMF’s main 500 MeV beamline (beamline 1A, BL1A), was recovered to build a228Th/212Pb generator with the ability to deliver up to 9–10 MBq of212Pb daily. Both lead isotopes were purified via solid phase extraction chromatography (Pb resin), and isolated in an acetate form ([203/212Pb]Pb(OAc)2) suitable for direct radiolabeling of chelators and bioconjugates. A series of cyclen-based chelators (herein referred to as DOTA-1Py, -2Py, and -3Py) along with established chelates DOTA and TCMC were evaluated for their ability to complex both203Pb and212Pb. All chelates incorporated212Pb/203Pb efficiently, with higher radiolabeling yields observed for the212Pb-complexes.Conclusion: The production of203Pb and212Pb was established using TRIUMF 13 MeV and 500 MeV cyclotrons, respectively. Both production methods provided radiometals suitable for subsequent radiolabeling reactions using known and novel chelates. Furthermore, the novel chelate DOTA-3Py may be a good candidate for biomolecule conjugation and further theranostic212Pb/203Pb studies.

17 July 2020 in Inorganic Chemistry
Verified
Journal Article
Closed access
ARAndrew K. H. Robertson
Andrew K. H. Robertson
BMBrooke L. McNeil
Brooke L. McNeil
HYHua Yang
Hua Yang
DGDenise Gendron
Denise Gendron
RPRandy Perron
Randy Perron
PSPaul Schaffer
Paul Schaffer

25 June 2020 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
HYHua Yang
Hua Yang
CZChengcheng Zhang
Chengcheng Zhang
ZYZheliang Yuan
Zheliang Yuan
CRCristina Rodriguez‐Rodriguez
Cristina Rodriguez‐Rodriguez
ARAndrew Robertson
Andrew Robertson
PSPaul Schaffer
Paul Schaffer

27 March 2020 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
LLLily Li
Lily Li
JRJulie Rousseau
Julie Rousseau
MJMaría de Guadalupe Jaraquemada-Peláez
María de Guadalupe Jaraquemada-Peláez
XWXiaozhu Wang
Xiaozhu Wang
ARAndrew Robertson
Andrew Robertson
COChris Orvig
Chris Orvig

6 August 2019 in EJNMMI Radiopharmacy and Chemistry
Verified
Journal Article
Open access
PDF file
CRCaterina F. Ramogida
Caterina F. Ramogida
ARAndrew Robertson
Andrew Robertson
UJUna Jermilova
Una Jermilova
CZChengcheng Zhang
Chengcheng Zhang
HYHua Yang
Hua Yang
PSPaul Schaffer
Paul Schaffer
Actinium-225 (225Ac, t1/2 = 9.9 d) is a promising candidate radionuclide for use in targeted alpha therapy (TAT), though the currently limited global supply has hindered the development of a suitable Ac-chelating ligand and 225Ac-radiopharmaceuticals towards the clinic. We at TRIUMF have leveraged our Isotope Separation On-Line (ISOL) facility to produce 225Ac and use the resulting radioactivity to screen a number of potential 225Ac-radiopharmaceutical compounds. MBq quantities of 225Ac and parent radium-225 (225Ra, t1/2 = 14.8 d) were produced and separated using solid phase extraction DGA resin, resulting in a radiochemically pure 225Ac product in > 98% yield and in an amenable form for radiolabeling of ligands and bioconjugates. Of the many polydentate picolinic acid (“pa”) containing ligands evaluated (H4octapa [N4O4], H4CHXoctapa [N4O4], p-NO2-Bn-H4neunpa [N5O4], and H6phospa [N4O4]), all out-performed the current gold standard, DOTA for 225Ac radiolabeling ability at ambient temperature. Moreover, a melanocortin 1 receptor-targeting peptide conjugate, DOTA-modified cyclized α-melanocyte-stimulating hormone (DOTA-CycMSH), was radiolabeled with 225Ac and proof-of-principle biodistribution studies using B16F10 tumour-bearing mice were conducted. At 2 h post-injection, tumour-to-blood ratios of 20.4 ± 3.4 and 4.8 ± 2.4 were obtained for the non-blocking (molar activity [M.A.] > 200 kBq/nmol) and blocking (M.A. = 1.6 kBq/nmol) experiment, respectively. TRIUMF’s ISOL facility is able to provide 225Ac suitable for preclinical screening of radiopharmaceutical compounds; [225Ac(octapa)]−, [225Ac(CHXoctapa)]−, and [225Ac(DOTA-CycMSH)] may be good candidates for further targeted alpha therapy studies.